

# Markus Magerl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2021050/publications.pdf>

Version: 2024-02-01

140  
papers

8,696  
citations

47006

47  
h-index

49909

87  
g-index

163  
all docs

163  
docs citations

163  
times ranked

4385  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 979-990.  | 5.7  | 33        |
| 2  | The international EAACI/GA <sup>2</sup> LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.                                      | 5.7  | 392       |
| 3  | The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1961-1990.  | 5.7  | 153       |
| 4  | Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, 4.  | 2.0  | 5         |
| 5  | The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.   | 3.5  | 37        |
| 6  | Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2022, 399, 945-955.                 | 13.7 | 28        |
| 7  | Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1188-1198.  | 5.7  | 28        |
| 8  | The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 691-700.  | 1.2  | 28        |
| 9  | Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 86. | 2.7  | 10        |
| 10 | Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 40-49.   | 6.5  | 39        |
| 11 | Analysis of genetic impact on smell impairment in patients with hereditary angioedema type 1 and 2. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1060-1062.   | 0.8  | 0         |
| 12 | Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1526-1532.  | 2.9  | 27        |
| 13 | Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 84-97.   | 6.5  | 16        |
| 14 | Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3744-3751.  | 3.8  | 17        |
| 15 | The Diagnostic Workup in Chronic Spontaneous Urticaria – What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.   | 3.8  | 21        |
| 16 | How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. <i>World Allergy Organization Journal</i> , 2021, 14, 100542.  | 3.5  | 11        |
| 17 | HAE patient self-sampling for biomarker establishment. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 399.  | 2.7  | 4         |
| 18 | Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.  | 5.7  | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Inducible Urticarias. , 2021, , 109-132.  |     | 0         |
| 20 | Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 2021, 11, e12089.   | 3.2 | 9         |
| 21 | Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 224-226.   | 5.7 | 15        |
| 22 | How to control recurrent angioedema using monoclonal antibody therapies?. Expert Opinion on Biological Therapy, 2020, 20, 1-4.  | 3.1 | 9         |
| 23 | International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.   | 3.8 | 43        |
| 24 | Development of the Angioedema Control Testâ€”A patientâ€™reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177. | 5.7 | 47        |
| 25 | Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.   | 0.8 | 6         |
| 26 | A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet Journal of Rare Diseases, 2020, 15, 221.  | 2.7 | 9         |
| 27 | Validation of the Angioedema Control Test (AECT)â€”A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.                                | 3.8 | 50        |
| 28 | Hereditary angioedema in children and adolescents â€” A consensus update on therapeutic strategies for Germanâ€™speaking countries. Pediatric Allergy and Immunology, 2020, 31, 974-989.  | 2.6 | 16        |
| 29 | A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergology International, 2020, 69, 443-449.  | 3.3 | 19        |
| 30 | Definition, aims, and implementation of GA<sup>2</sup>/LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.  | 5.7 | 29        |
| 31 | The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organization Journal, 2020, 13, 100475.  | 3.5 | 13        |
| 32 | Guideline: Hereditary angioedema due to C1 inhibitor deficiency. Allergo Journal International, 2019, 28, 16-29.  | 2.0 | 32        |
| 33 | Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.  | 5.7 | 26        |
| 34 | Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatric Allergy and Immunology, 2019, 30, 562-568.   | 2.6 | 18        |
| 35 | Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1747-1754.                               | 2.4 | 20        |
| 36 | Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1793-1802.e2.                                    | 3.8 | 58        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 163-169.  | 2.4  | 8         |
| 38 | Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 477-478.  | 0.8  | 51        |
| 39 | The EAACI/GA <sup>2</sup> LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1393-1414.  | 5.7  | 1,008     |
| 40 | Executive summary of the methods report for "The EAACI/GA <sup>2</sup> LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update"™. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1145-1146. | 5.7  | 74        |
| 41 | The international WAO/EAACI guideline for the management of hereditary angioedema "The 2017 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1575-1596.  | 5.7  | 365       |
| 42 | The international WAO/EAACI guideline for the management of hereditary angioedema " the 2017 revision and update. <i>World Allergy Organization Journal</i> , 2018, 11, 5.   | 3.5  | 45        |
| 43 | Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 73.  | 2.7  | 114       |
| 44 | Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 476-477.  | 0.8  | 1         |
| 45 | Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The "OPUS" study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1871-1880.   | 5.7  | 31        |
| 46 | Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 638-649.  | 2.9  | 187       |
| 47 | Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2108.   | 7.4  | 174       |
| 48 | Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. <i>Clinical and Translational Allergy</i> , 2018, 8, 42.  | 3.2  | 29        |
| 49 | Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. <i>Gene</i> , 2018, 667, 76-82.   | 2.2  | 32        |
| 50 | Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2018, 379, 352-362.  | 27.0 | 89        |
| 51 | Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2073-2075.  | 5.7  | 22        |
| 52 | Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 110-112.  | 1.0  | 24        |
| 53 | Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema. <i>Allergy and Rhinology</i> , 2017, 8, ar.2017.8.0192.   | 1.6  | 21        |
| 54 | Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1142-1145.   | 3.8  | 17        |



| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 963-971.   | 3.8 | 50        |
| 74 | BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB278.                                     | 2.9 | 4         |
| 75 | Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB192.  | 2.9 | 5         |
| 76 | Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1319-1328.  | 5.7 | 59        |
| 77 | Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB192.  | 2.9 | 1         |
| 78 | An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2043-2045.  | 2.4 | 35        |
| 79 | <i>F12</i> 46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1661-1664.  | 5.7 | 42        |
| 80 | Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermatographism. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 399-403.   | 1.3 | 25        |
| 81 | Hereditary angioedema: Molecular and clinical differences among European populations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 570-573.e10.   | 2.9 | 63        |
| 82 | Subcutaneous Human C1-Inhibitor with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema: Results of a Randomized, Double-Blind, Dose-Ranging, Crossover Study. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB278. | 2.9 | 4         |
| 83 | Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 298-303.  | 1.3 | 44        |
| 84 | Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 971-978.  | 0.8 | 39        |
| 85 | Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. <i>Allergy, Asthma and Clinical Immunology</i> , 2013, 9, 29.   | 2.0 | 107       |
| 86 | Miltefosine: a novel treatment option for mast cell-mediated diseases. <i>Journal of Dermatological Treatment</i> , 2013, 24, 244-249.  | 2.2 | 10        |
| 87 | Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e363-9.  | 2.4 | 23        |
| 88 | Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 949-952.   | 5.7 | 46        |
| 89 | Practical algorithm for diagnosing patients with recurrent wheals or angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 816-819.   | 5.7 | 53        |
| 90 | Practical Approach to Self-Administration of Intravenous C1-INH Concentrate: A Nursing Perspective. <i>International Archives of Allergy and Immunology</i> , 2013, 161, 17-20.   | 2.1 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.                                       | 5.7 | 147       |
| 92  | A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clinical and Experimental Dermatology, 2013, 38, 360-366. | 1.3 | 35        |
| 93  | Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy and Asthma Proceedings, 2012, 33, 145-156.   | 2.2 | 142       |
| 94  | Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.                                | 5.7 | 182       |
| 95  | Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies. European Journal of Pediatrics, 2012, 171, 1339-1348.  | 2.7 | 80        |
| 96  | WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, 182-199.  | 3.5 | 264       |
| 97  | Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H <sub>1</sub> -antihistamine dose escalation. British Journal of Dermatology, 2012, 166, 1095-1099.    | 1.5 | 53        |
| 98  | Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.                       | 1.9 | 28        |
| 99  | Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.   | 2.1 | 133       |
| 100 | Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 303-305.                       | 5.7 | 61        |
| 101 | New topics in bradykinin research. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1397-1406.   | 5.7 | 146       |
| 102 | Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.   | 1.5 | 18        |
| 103 | Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120. | 2.4 | 21        |
| 104 | Long-term prophylaxis of hereditary angioedema with androgen derivatives: a critical appraisal and potential alternatives. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-107.        | 0.8 | 28        |
| 105 | Langzeitprophylaxe des hereditären Angioödems mit Androgenderivaten: kritische Bewertung und mögliche Alternativen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-108.               | 0.8 | 18        |
| 106 | Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.   | 1.4 | 22        |
| 107 | High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.   | 1.3 | 110       |
| 108 | Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.                                  | 0.8 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Erfolgreiche Behandlung des hereditären Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.  | 0.8 | 7         |
| 110 | Hereditary angioedema: an update on available therapeutic options. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-672.   | 0.8 | 16        |
| 111 | Hereditäres Angioödem: Update zu verfügbaren Therapieoptionen. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-673.   | 0.8 | 14        |
| 112 | Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.   | 1.5 | 49        |
| 113 | Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. British Journal of Dermatology, 2010, 162, 674-676.   | 1.5 | 59        |
| 114 | Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 78-83.   | 5.7 | 102       |
| 115 | Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.  | 5.7 | 46        |
| 116 | Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.   | 2.9 | 59        |
| 117 | Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.   | 1.3 | 21        |
| 118 | Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.   | 2.9 | 22        |
| 119 | Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. Mycoses, 2009, 52, 334-338.   | 4.0 | 25        |
| 120 | The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 927-936.               | 5.7 | 145       |
| 121 | The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA <sup>2</sup> LEN/EDF/UNEV consensus panel recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1715-1721. | 5.7 | 143       |
| 122 | Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2009, 123, 705-706.   | 2.9 | 67        |
| 123 | Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. Annals of Allergy, Asthma and Immunology, 2009, 102, 495-499.   | 1.0 | 17        |
| 124 | Prevalence and relevance of skin autoreactivity in chronic urticaria. Expert Review of Dermatology, 2009, 4, 655-663.   | 0.3 | 3         |
| 125 | Non-pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. Experimental Dermatology, 2008, 17, 427-435.   | 2.9 | 47        |
| 126 | Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.  | 5.7 | 149       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 955-961.   | 2.9 | 75        |
| 128 | Control of <i>Pseudomonas aeruginosa</i> Skin Infections in Mice Is Mast Cell-Dependent. <i>American Journal of Pathology</i> , 2007, 170, 1910-1916.  | 3.8 | 80        |
| 129 | Successful treatment of delayed pressure urticaria with anti-TNF- $\alpha$ . <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 752-754.   | 2.9 | 81        |
| 130 | Acquired cold urticaria symptoms can be safely prevented by ebastine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1465-1468.   | 5.7 | 38        |
| 131 | Acquired cold urticaria: clinical picture and update on diagnosis and treatment. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 241-245.   | 1.3 | 105       |
| 132 | Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. <i>Dermatology</i> , 2006, 212, 150-159.   | 2.1 | 120       |
| 133 | Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. <i>British Journal of Dermatology</i> , 2006, 154, 294-298.   | 1.5 | 189       |
| 134 | Limitations of human occipital scalp hair follicle organ culture for studying the effects of minoxidil as a hair growth enhancer. <i>Experimental Dermatology</i> , 2004, 13, 635-642.   | 2.9 | 31        |
| 135 | Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1224-1225.  | 2.9 | 63        |
| 136 | Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme During the Hair Growth Cycle: Implications for Growth Control and Hair Follicle Transformations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2003, 8, 80-86. | 0.8 | 51        |
| 137 | Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme: Implications for Hair Growth Control. <i>Journal of Investigative Dermatology</i> , 2003, 120, 895-904.   | 0.7 | 135       |
| 138 | Simple and rapid method to isolate and culture follicular papillae from human scalp hair follicles. <i>Experimental Dermatology</i> , 2002, 11, 381-385.   | 2.9 | 84        |
| 139 | Patterns of Proliferation and Apoptosis during Murine Hair Follicle Morphogenesis. <i>Journal of Investigative Dermatology</i> , 2001, 116, 947-955.   | 0.7 | 83        |
| 140 | Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE). <i>Frontiers in Allergy</i> , 0, 3, .  | 2.8 | 2         |